The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase 2 study of carboplatin plus irinotecan (CI) versus carboplatin plus amrubicin (CA) for extensive disease small-cell lung cancer (ED-SCLC): NJLCG0901.
Yosuke Kawashima
No relevant relationships to disclose
Naoto Morikawa
No relevant relationships to disclose
Shunichi Sugawara
No relevant relationships to disclose
Makoto Maemondo
No relevant relationships to disclose
Toshiyuki Harada
No relevant relationships to disclose
Masao Harada
No relevant relationships to disclose
Akira Inoue
No relevant relationships to disclose
Yuka Fujita
No relevant relationships to disclose
Terufumi Kato
No relevant relationships to disclose
Hiroshi Yokouchi
No relevant relationships to disclose
Hiroshi Watanabe
No relevant relationships to disclose
Kazuhiro Usui
No relevant relationships to disclose
Toshiro Suzuki
No relevant relationships to disclose
Satoshi Oizumi
No relevant relationships to disclose
Hiroki Nagai
No relevant relationships to disclose
Mariko Kanbe
No relevant relationships to disclose
Toshihiro Nukiwa
Consultant or Advisory Role - Boehringer Ingelheim; Shionogi
Honoraria - Chugai Pharma
Other Remuneration - Sekisui Medical